Skip to main content

Bir Dawn Carter

No open-market purchases or sales filed in the past year.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Bir Dawn Carter as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

RETA Reata Pharmaceuticals Inc

Chief Commercial Officer6 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 17, 2023 (view filing)Aug 15-162 daysBir Dawn CarterChief Commercial OfficerSSaleClass A common stock−1.21K$168.81−$203.4K−3.4%33.8K after2 lots
Aug 1, 2023 (view filing)Jul 284 daysBir Dawn CarterChief Commercial OfficerSSaleClass A common stock−40.0K$164.54−$6.58M−53.3%35.0K after10b5-1
May 17, 2023 (view filing)May 15-162 daysBir Dawn CarterChief Commercial OfficerSSaleClass A common stock−1.31K$83.78−$109.8K−4.1%30.9K after2 lots
Mar 15, 2023 (view filing)Mar 132 daysBir Dawn CarterChief Commercial OfficerSSaleClass A common stock−9.32K$86.77−$808.4K−22.4%32.2K after
Mar 8, 2023 (view filing)Mar 6-72 daysBir Dawn CarterChief Commercial OfficerSSaleClass A common stock−97.0K$87.67−$8.50M−70.0%41.5K after5 lots
Mar 6, 2023 (view filing)Mar 33 daysBir Dawn CarterChief Commercial OfficerSSaleClass A common stock−2.17K$88.25−$191.1K−4.3%48.5K after